Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — Corporate Update (May 2011)
33 slides from Aspen Pharmacare's corporate update, May 10, 2011
Slide 1: Aspen Investor Visit Port Elizabeth Site, South Africa
Aspen Investor Visit Port Elizabeth Site, South Africa 10 May 2011
Slide 2: Aspen's Global Footprint
Aspen’s Global Footprint C = Combined sales, marketing, distribution and manufacturing centres G = Group headquarters M = Manufacturing centres S = Sales, marketing and distribution centres 1. G Durban, South Africa 2. C Cape Town, South Africa 3. C Johannesburg, South Africa 4. M Port Elizabeth, So
Slide 3: Commitment to making a difference in health
We remain committed to making a meaningful difference in the health of all those using Aspen medicines globally, and to increase our contribution to the lives of people in the many markets we serve across the globe through the manufacture and supply of high-quality, affordable medicines in a respons
Slide 4: Aspen's Manufacturing Competitive Advantages
Aspen’s Manufacturing Competitive Advantages Manufacturing capacity and capability is aligned to the Group’s growth strategy • Aspen’s strength lies in its ability to supply high volumes of products reliably with 4.8 billion tablets being manufactured currently • Manufacturing capabilities at the Po
Slide 5: Evolution of Aspen's Manufacturing Base
Evolution of Aspen’s Manufacturing Base • Aspen General Facility has been on the present site for approximately 70 years • Acquired by Aspen from South African Druggists in March 1999, together with facilities in East London and Johannesburg • Mainly supplied the South African market • Within 12 yea
Slide 6: Current Allocation of Domestic and International Volumes
Current Allocation of Domestic and International Volumes • Manufactured products are supplied to Europe, Latin America and China • Additional international volumes are in the process of being introduced to the Port Elizabeth facility Regulatoryapprovals are required by the relevant territory, per
Slide 7: Strategic Manufacturing Partnerships
Strategic Manufacturing Partnerships Boehrin ger Nevirapine Ingelhei m Lamivudine, Zidovudine, GSK Combivir, Epivir & Others Stavudine, Didanosine, BMS Atazanavir Gilead Tenofovir & Emtricitabine MSD Efavirenz Iroko Aldomet and Indocid Cycloserine and Eli Lilly Capreomycin Bayer Nur- Isterate Inject
Slide 8: Aerial view of Aspen's Global Manufacturing Base in Port Elizabeth
Aerial view of Aspen’s Global Manufacturing Base in Port Elizabeth Technical Centre UNIT 3 : General Facility UNIT 2 : Oral Solids UNIT 1 : Packing UNIT 1 : Oral Solids UNIT 1 : Bottling Plant Sterile Lyophillisation & Eye drop Facility Sterile Warehouse 8
Slide 9: Regulatory Authorities Relevant to South African Operations
Regulatory Authorities Relevant to South African Operations Regulator Unit 1 Unit 2 Unit 3 SVP MP SVP HP East ADC ACW y London Authority MCC X X X X X X X X FDA X # # # X MHRA X # # # X WHO X # # # X TGA X # # # X Anvisa X # # # X (Brazil) High volume Small to medium End Eye High Semi-solids, Wareho
Slide 10: Strategic Rationalisation Initiatives
Strategic Rationalisation Initiatives Significant efficiencies and cost reductions have been realised through the consolidation of the Port Elizabeth site management systems: • Site management and facilities support functions have been consolidated under a single management structure Historically
Slide 11: Unit 1 – Oral Solid Dosage Facility
Unit 1 – Oral Solid Dosage Facility • In 2005, an investment was made in the construction of an FDA- approved facility in response to the HIV/AIDS pandemic in Africa • High volume production of tablets and capsules • The facility was successfully re-inspected by FDA, MRHA and WHO in 2010 No major
Slide 12: Unit 2 – Oral Solid Dosage Facility
Unit 2 – Oral Solid Dosage Facility Unit 2 • 2.0 billion tablets are manufactured in this area • Total capacity = 3 billion tablets Part 2A – Fluid Bed Dried (FBD) products • Small to medium volume solids production for selected regulated markets • Reformulated products and investment in new equipme
Slide 13: Unit 3 – General Facility
Unit 3 – General Facility • A phased process for the transfer of products to Unit 1 and Unit 2 is in progress • Bulk tablet manufacturing at Unit 3 will be decommissioned by end June 2011 • Semi-solids (creams, ointments and suppositories) and Liquid Lennon Dutch Medicines have been transferred to E
Slide 14: Flow Diagram of the Tabletting Processes
Flow Diagram of the Tabletting Processes Air Dispensing Fluidised Scale Sievin Bed Dryer g Granulat Ai ion r Magnesium Blendi Stearate ng Sievin g Compress Packagi ion ng Coating / Capsule fill 14
Slide 15: Focus on Continuous Improvement Initiatives
Focus on Continuous Improvement Initiatives Introduction of the Fluid Bed Drying Process • The older oven drying technology Wet granule obtained during tablet manufacture is dried by spreading materials onto trays inside an oven Process time is relatively long, requiring an average of 8 - 16 hou
Slide 16: Focus on Continuous Improvement Initiatives
Focus on Continuous Improvement Initiatives • Doubling of batch sizes to reduce set-up time between batches and thereby optimise equipment utilisation All Unit 1 manufactured and all Unit 1/3 packed products completed Unit 2 manufactured products in progress Impact: Reduction of total annual set
Slide 17: Focus on Continuous Improvement Initiatives
Focus on Continuous Improvement Initiatives • Barcode status labelling of materials implemented to reduce handling activities Impact: More efficient process through an instantaneous scanning process. Reduction in labelling time - manual capturing and labelling change used take up to one shift • Eval
Slide 18: In-house Manufacturing Cost Analysis
In-house Manufacturing Cost Analysis Allocation of Production ConvCosts (including ARV’s) ersio n costs 36% Mate Allocation of Conversion costs rials De Ot cost pr he 64% eci r ati 18 on % 17 La % bo ur Ele 58 Allocation of Production ctr % ConvCosts ici ersio ty ( excluding n ARV’s) 7% costs 47% Ma
Slide 19: Impact of Continuous Improvement on Recoveries
Impact of Continuous Improvement on Recoveries Unit 1 Recoveries +39% +78% +120% 2007 2008 2009 2010 19
Slide 20: Prospects in Solids Manufacturing at the Port Elizabeth Site
Prospects in Solids Manufacturing at the Port Elizabeth Site • The redundant areas in Unit 3 will be converted into specialised manufacturing areas including High potency suite (HPS) Toxic suite (TS) • Following approval of the final design, construction of the HPS and TS will commence in the 20
Slide 21: East London Site
East London Site API Store Oral Contraceptive s General Manufacture An employee in the Oral Contracepti Aerial view of East London plant wearing the necessary protective 21
Slide 22: East London Multi-Purpose Site
East London Multi-Purpose Site General Facility • Highly flexible, small volume, niche, solids manufacture, including low dose drugs • Significant investment has been made into upgrading the East London facility for the manufacture of semi-solids and Dutch medicines Oral Contraceptive Facility • The
Slide 23: The Steriles Facility
The Steriles Facility • Project commenced in 2007, presenting challenging complexities of design, technology, technical compliance requirements and specialist skills • Specialist facility for the manufacture of eye drops, lyophilised vials and sterile injectables, including hormonal vials and ampoul
Slide 24: Steriles Facility – Multi-Product Suite
Steriles Facility – Multi-Product Suite Lines 1 and 2 • High volume eye drops with an annual capacity of 42 million units • Close to 30 million units being exported to US and Canada under a manufacturing contract with Prestige Brands • Aspen’s Eye Gene range has been introduced; remaining Aspen rang
Slide 25: Steriles Facility – High Potency Suite
Steriles Facility – High Potency Suite Line 4 • High volume ampoule filling capability for hormonal injectables - a niche capability for filling and packing oily solutions which is very relevant to emerging markets Validation batches of Bayer Nur-Isterate are scheduled for 2011 • Aspen’s Lenasone,
Slide 26: Procurement Initiatives
Procurement Initiatives • Comprehensive understanding of products / materials, driving factors and market factors • Ability to effectively benchmark product prices, quality and supplier service to ensure that we are procuring optimally • Longstanding relationships have been established with internat
Slide 27: Allocation of Procurement Currencies
Allocation of Procurement Currencies • Most API’s and excipients are purchased mainly from Asia: India China EUR Other ZA 1% 5% R • Packaging materials are largely purchased 33 from South African suppliers % U S D 61 • Aspen received an A-rating from % Empowerdex in the preferential procurement
Slide 28: Training and Development
Training and Development • 140 new/ongoing 2010/11 Learnerships are in place, covering the fields of Business Administration, Equipment Setting and Operation, Safety Controls, Pharmaceutical Controls, etc. • Additional Laboratory and Warehousing Learnerships are in development for 2011/2012 • 20 add
Slide 29: Environmental Sustainability Initiatives
Environmental Sustainability Initiatives Carbon Footprint • Sophisticated air handling systems are in place to purify and filter the air discharged from the production areas • Sampling was done in Port Elizabeth and East London for Sulphur Dioxide, Nitrous Oxide, Volatile Organic Compounds and parti
Slide 30: Environmental Sustainability Initiatives
Environmental Sustainability Initiatives Conservation of Electricity • A target of 4% reduction in monthly energy consumption has been achieved through the installation of energy saving lighting in Liquids and Solids packing areas, and installation of lighting-off motion detectors across Port Elizab
Slide 31: Social Sustainability Initiatives
Social Sustainability Initiatives • We have secured job security for our permanent employees despite recessionary pressures facing manufacturers in South Africa • No permanent employees were made redundant by the implemented continuous improvement initiatives • The Disabling Frequency Ratio of 0.63
Slide 32: Risks and Challenges
Risks and Challenges • Realisation of awarded public sector volumes Mitigation: International volumes are being introduced to Port Elizabeth • Impact of inflation and currency movements on cost of goods Mitigation: Benefits from continuous improvement initiatives and effective procurement strategies
Slide 33: Generics Bulletin Report : May 2010
Generics Bulletin Report : May 2010 Teva [incl Ratiopharm] (1,4,5) Sandoz Mylan(2) Watson(3) (1) Sales exclude Ratiopharm; brand sales include Copaxone sales of USD2.83 million Stada(4) (2) Generics sales growth was 9.2% Hospira(6) (3) Includes Arrow from December 2009 Perrigo(7,8) (4) Reported in E
Aspen Pharmacare Holdings — Corporate Update (May 2011) on 6ix